|(G;T)||complex; generally greater risk for cancer progression|
|(T;T)||0||complex; generally greater risk for cancer progression|
What's the importance of this? FcgRIIIa stimulatory receptors are expressed by most cells in the immune system, including monocytes, dendritic cells, macrophages, natural killer cells, platelets and endothelial cells, as well as a subpopulation of T-cells. FcgR isoforms have been linked to the pathogenic consequences triggered by autoantibodies or immune complexes in autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), as well as to the efficacy of some immunotherapeutic treatments such as rituximab.
Many studies have been published about this FCGR3A SNP, roughly divided by either disorder or treatment as follows:
- HIV to AIDs, including susceptibility and progression:
- In a study of 2 cohorts of men infected with HIV, the rs396991(T;T) (ie F/F) genotype was underrepresented in patients with Kaposi's sarcoma, whereas the heterozygous genotype was associated with it's development. A similar association was observed between rs396991 genotypes and human herpesvirus-8 (HHV-8) seropositivity.[PMID 10733511]
- Crohn's disease
- Rheumatoid arthritis
- Meta-analysis of 10 different studies concluded that amongst European subjects (and not Asians), the VV (rs396991(G;G)) genotype was associated with increased risk for rheumatoid arthritis, with an odds ratio of 1.374 (CI: 1.101-1.714, p = 0.005) as compared to the FF genotype.[PMID 18843786]
- Although rs396991 is unlikely to play a major role by itself in susceptibility to rheumatoid arthritis, the presence of the rs396991(G) high-binding allele may predispose shared epitope positive individuals to the disease.[PMID 12734884]
Classifying the reports by immunotherapeutic treatment studied yields the following:
- Studies involving rituximab:
- In a study of ~200 Korean patients, the FCGR3A valine (V) allele was significantly correlated with a higher complete response rate to rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (R-CHOP) therapy compared with the phenylalanine (F) allele (88% in V/V vs 79% in V/F vs 50% in F/F; p = .002), although it did not correlate with survival in patients with diffuse large B-cell lymphoma (DLBCL).[PMID 16609067]
- In a study of 58 Croatian patients with diffuse large B-cell lymphoma, rs396991 did not influence response, event-free or overall survival.[PMID 17606457]
- A study of 49 patients receiving rituximab for previously untreated follicular non-Hodgkin's lymphoma concluded that rs396991(G;G) patients have a 75% to 90% chance of experiencing a clinical response to rituximab monotherapy, whereas patients with at least one rs396991(T) allele have a 25% to 51% chance of responding.[PMID 11806974]
- Another study of 89 patients with follicular lymphoma found that rs396991 genotype was associated with the response rate and freedom from progression after treatment with rituximab. [PMID 12975461]
- Studies involving cetuximab:
- Studies involving trastuzumab:
- A retrospective analysis of 1,251 patients included in a phase III trial of women with ERBB2/HER2-positive breast cancer concluded that rs396991(G) carriers (i.e. FCGR3A-158 V carriers) benefit the most, as measured by disease-free survival, from trastuzumab use compared to rs396991(T:T) (i.e. FCGR3A-158 F/F) genotypes.[PMID 27812689]
[PMID 19140833] Linkage and association study of FcgammaR polymorphisms in celiac disease
[PMID 19640933] FCGR2B gene polymorphism rather than FCGR2A, FCGR3A and FCGR3B is associated with anti-GBM disease in Chinese
[PMID 20149216] Fcgamma receptor polymorphisms and their association with periodontal disease: a meta-analysis
[PMID 20439102] Analysis of MIF, FCGR2A and FCGR3A gene polymorphisms with susceptibility to pulmonary tuberculosis in Moroccan population
[PMID 21208440] Polymorphisms of CD16A and CD32 Fcgamma Receptors and Circulating Immunocomplexes in Meniere Disease: a case-control study
[PMID 21723269] Genetic profiling of GSTP1, DPYD, FCGR2A, FCGR3A and CCND1 genes in an Argentinian population [PMID 18759263] Features associated with, and the impact of, hemolytic anemia in patients with systemic lupus erythematosus: LX, results from a multiethnic cohort.
[PMID 19421223] Fcgamma receptors: structure, function and role as genetic risk factors in SLE.
[PMID 20018222] Association of polymorphism in FcGR3A gene and progression of low-grade precursor lesions of cervical carcinoma.
[PMID 20400988] A single-nucleotide polymorphism of the Fcgamma receptor type IIIA gene in the recipient predicts transplant outcomes after HLA fully matched unrelated BMT for myeloid malignancies.
[PMID 20508037] Copy number, linkage disequilibrium and disease association in the FCGR locus.
[PMID 22417159] DNA sequence variation and regulation of genes involved in pathogenesis of pulmonary tuberculosis.
[PMID 23075294] Association of the FCGR3A-158F/V Gene Polymorphism with the Response to Rituximab Treatment in Spanish Systemic Autoimmune Disease Patients
|qualified_impact||Insufficiently evaluated pharmacogenetic|
[PMID 23680410] Detection of the FCGR3a polymorphism using a real-time polymerase chain reaction assay
[PMID 24375423] FcγRIIIa SNPs and haplotypes affect human IgG binding and association with lupus nephritis in African Americans
[PMID 24586589] Functional fcgamma receptor polymorphisms are associated with human allergy [PMID 22922574] Fcgamma receptor polymorphisms do not predict response to intravenous immunoglobulin in myasthenia gravis.
[PMID 23649770] Associations between FCGR2A rs1801274, FCGR3A rs396991, FCGR3B NA1/NA2 polymorphisms and periodontitis: a meta-analysis.
[PMID 24782186] Fcγ Receptor IIIa Single-Nucleotide Polymorphisms and Haplotypes Affect Human IgG Binding and Are Associated With Lupus Nephritis in African Americans
|Disease||rituximab response - Efficacy cetuximab response - Efficacy trastuzumab response - Efficacy|
|CLNDBN||rituximab response - Efficacy cetuximab response - Efficacy trastuzumab response - Efficacy|
|CLNSRC||PharmGKB Clinical Annotation PharmGKB|
|CLNACC||RCV000211135.1, RCV000211261.1, RCV000211344.1,|